These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 17460617)
1. Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an FMRI study. Jager G; de Win MM; van der Tweel I; Schilt T; Kahn RS; van den Brink W; van Ree JM; Ramsey NF Neuropsychopharmacology; 2008 Jan; 33(2):247-58. PubMed ID: 17460617 [TBL] [Abstract][Full Text] [Related]
2. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417 [TBL] [Abstract][Full Text] [Related]
3. Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task. Roberts GM; Nestor L; Garavan H Brain Res; 2009 Oct; 1292():71-81. PubMed ID: 19631624 [TBL] [Abstract][Full Text] [Related]
4. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709 [TBL] [Abstract][Full Text] [Related]
5. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Schilt T; de Win MM; Koeter M; Jager G; Korf DJ; van den Brink W; Schmand B Arch Gen Psychiatry; 2007 Jun; 64(6):728-36. PubMed ID: 17548754 [TBL] [Abstract][Full Text] [Related]
6. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds. Bedi G; Redman J Psychol Med; 2008 Sep; 38(9):1319-30. PubMed ID: 18226286 [TBL] [Abstract][Full Text] [Related]
7. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. Parrott AC J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474 [TBL] [Abstract][Full Text] [Related]
8. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910 [TBL] [Abstract][Full Text] [Related]
9. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Daumann J; Fischermann T; Heekeren K; Thron A; Gouzoulis-Mayfrank E Biol Psychiatry; 2004 Sep; 56(5):349-55. PubMed ID: 15336517 [TBL] [Abstract][Full Text] [Related]
10. Evidence of increased activation underlying cognitive control in ecstasy and cannabis users. Roberts GM; Garavan H Neuroimage; 2010 Aug; 52(2):429-35. PubMed ID: 20417713 [TBL] [Abstract][Full Text] [Related]
11. Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls. Cousijn J; Vingerhoets WA; Koenders L; de Haan L; van den Brink W; Wiers RW; Goudriaan AE Addict Biol; 2014 Mar; 19(2):282-93. PubMed ID: 24589297 [TBL] [Abstract][Full Text] [Related]
12. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Jager G; de Win MM; Vervaeke HK; Schilt T; Kahn RS; van den Brink W; van Ree JM; Ramsey NF Psychopharmacology (Berl); 2007 Aug; 193(3):403-14. PubMed ID: 17476480 [TBL] [Abstract][Full Text] [Related]
13. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Milani RM; Parrott AC; Schifano F; Turner JJ Hum Psychopharmacol; 2005 Jun; 20(4):249-61. PubMed ID: 15816011 [TBL] [Abstract][Full Text] [Related]
14. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. Gouzoulis-Mayfrank E; Daumann J J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477 [TBL] [Abstract][Full Text] [Related]
15. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479 [TBL] [Abstract][Full Text] [Related]
16. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Rogers G; Elston J; Garside R; Roome C; Taylor R; Younger P; Zawada A; Somerville M Health Technol Assess; 2009 Jan; 13(6):iii-iv, ix-xii, 1-315. PubMed ID: 19195429 [TBL] [Abstract][Full Text] [Related]
17. Everyday and prospective memory deficits in ecstasy/polydrug users. Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N J Psychopharmacol; 2011 Apr; 25(4):453-64. PubMed ID: 20123936 [TBL] [Abstract][Full Text] [Related]
18. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective. Medina KL; Shear PK; Corcoran K J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911 [TBL] [Abstract][Full Text] [Related]